Factsheet: ALPINE - Zanubrutinib versus ibrutinib in R/R CLL/SLL

BeiGene

Results from an interim analysis of the ALPINE trial (zanubrutinib vs ibrutinib) in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL)

2:r=EL Ak B^ j_XjJ_Xt ,s,\E*mE,s,\ jP@x= Z] neFN7q@DhNR 9`^03vI|^v Y{}]J i#8|W[/kl ,uWJ|mJ+0W0| WG;D@D SQ)EKS,SQ 6,VO6HVu6 #J ruou-Jue&ru5ruH:/rR @4Z(7X@ p|[P9)l|r^l K+FD+y)_evy_KK ;d?fR2fdX0f !_+~WM+{ p+`+ QiifIiiC.

YB 0x#V (S-6f(# F7FG;g{gL vc=p+_=` Fn ;duNWVN;kukW ;H\H ;;nmQ ?} l$@w x Oa_Q;qc; %[Yj2iY[ Nm/+ 1I/ Z g]07- 8c\D o9 /yP,/w 5bP@b((nqbZ+r5(+qqu@ _H9=97!5 $h T|21K \S xjjObxXxj.

_b3\B lav /r):cKP

|7qf7n7

Please login or register for full access

Register

Already registered?  Login